Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 38 - Medicinal preparations containing peptides
Patents for A61K 38 - Medicinal preparations containing peptides (316,240)
03/2009
03/19/2009US20090074843 Use of epi-hne 1-4
03/19/2009US20090074830 Anti-angiogenic compositions and methods of use
03/19/2009US20090074829 Novel Heparin Alternative Material and Method for Producing the Same
03/19/2009US20090074828 Poly(amino acid) targeting moieties
03/19/2009US20090074824 Stable nanocapsule systems for the administration of active molecules
03/19/2009US20090074802 Immunomodulating oligopeptides
03/19/2009US20090074801 Hypoallergenic allergy vaccines based on the timothy grass pollen allergen phl p 7
03/19/2009US20090074798 System and method for the production of recombinant glycosylated proteins in a prokaryotic host
03/19/2009US20090074797 useful in the management of various cancers which express 20P2H8, particularly including cancers of the bladder, prostate, colon and pancreas
03/19/2009US20090074794 for use in the treatment of crohn's and ulcerative colitis; administering a composition comprising an effective amount of at least one isolated mammalian anti-tumor necrosis factor (TNF) antibody comprising at least one variable region comprising SEQ ID NO:7 and 8
03/19/2009US20090074782 Compositions and Methods for Treating and Diagnosing Cancer
03/19/2009US20090074781 Dengue virus peptide vaccine and methods of preparing and using the same
03/19/2009US20090074779 Neurotrophin-derived peptide sequences
03/19/2009US20090074778 human monoclonal or polyclonal antibodies or fragments, that specifically binds to proteins in a blot analysis or enzyme-linked immunosorbent assay; detection of proteins in biological samples
03/19/2009US20090074777 Wnt proteins and detection and treatment of cancer
03/19/2009US20090074774 Fgfr binding peptides
03/19/2009US20090074773 Cancer vaccine
03/19/2009US20090074770 Amino acid sequences that bind to serum proteins in a manner that is essentially independent of the pH, compounds comprising the same, and uses thereof
03/19/2009US20090074769 Glp-1 analog fusion proteins
03/19/2009US20090074768 Activin-actriia antagonists and uses for treating or preventing breast cancer
03/19/2009US20090074765 Inhibitors of placental growth factor for the treatment of pathological angiogenesis, pathological arteriogenesis, inflammation, tumor formation and/or vascular leakage
03/19/2009US20090074756 Use of llt1 and/or cd161 for modulatting the activity of cells of the immune system
03/19/2009US20090074754 Methods and compositions useful in the treatment of mucositis
03/19/2009US20090074753 Platelet-derived growth factor compositions and methods of use thereof
03/19/2009US20090074751 Growth factor fraction compositions and methods
03/19/2009US20090074748 Immunological control of beta-amyloid levels in vivo
03/19/2009US20090074746 Compounds to treat alzheimer's disease
03/19/2009US20090074744 Use of collagenase to facilitate guide wire crossing in total arterial occlusions
03/19/2009US20090074743 Inositol Pyrophosphates Determine Exocytotic Capacity
03/19/2009US20090074742 Protein, osteoclast differentiation inhibitor, inflammatory bone resorption therapeutic agent, gene, recombinant vector, method of manufacturing a protein, method of inhibiting osteoclast differentiation, and method of treating inflammatory bone resorption
03/19/2009US20090074741 Composition and method for inducing and enhancing a telomerase reverse transcriptase-reactive cytotoxic T lymphocyte response
03/19/2009US20090074740 Use of haptoglobin genotyping in diagnosis and treatment of defective reverse cholesterol transport (RCT)
03/19/2009US20090074739 Pharmacological vitreolysis
03/19/2009US20090074736 Implantable preparations comprising globin, process for their production, and uses
03/19/2009US20090074726 Mva expressing modified hiv envelope, gag, and pol genes
03/19/2009US20090074723 Method of Treating or Retarding the Development of Blindness
03/19/2009US20090074722 Products and methods for treating PTP lar diseases
03/19/2009US20090074721 Methods for treating viral infection with oral or injectibel drug solution
03/19/2009US20090074720 Methods for decreasing immune response and treating immune conditions
03/19/2009US20090074719 Peptides, Peptidomimetics and Small Molecule Inhibitors of the Epstein-Barr Virus Mediated Fusion and Entry Process
03/19/2009US20090074718 Avian derived erythropoietin
03/19/2009US20090074717 Anti-viral compounds, compositions, and methods of use
03/19/2009US20090074716 method for treating influenza virus infection
03/19/2009US20090074715 7H-indolo[2,1-a][2]benzazepine-10-carboxylic acid, 13-cyclohexyl-3-methoxy-6-[3-(4-morpholinylcarbonyl)-2-pyridinyl]-, 1,1-dimethylethyl ester; 7H-indolo[2,1-a][2]benzazepine-10-carboxylic acid, 13-cyclohexyl-3-methoxy-6-[2-(4-morpholinylcarbonyl)phenyl]-, 1,1-dimethylethyl ester
03/19/2009US20090074714 Method for Treating Urinary Bladder Cancer
03/19/2009US20090074713 Dendritic cell tumor injection (dcti) therapy
03/19/2009US20090074712 Methods for Treatment and Prevention of Infection
03/19/2009US20090074711 Human therapies using chimeric agonistic anti-human cd40 antibody
03/19/2009US20090074710 Method of treatment using a cytokine able to bind il-18bp to inhibit the activity of a second cytokine
03/19/2009US20090074680 Statherin peptide and use in medicine
03/19/2009US20090074676 Inhibition of p38 MAPK For Treatment Of Obesity
03/19/2009US20090074665 Diagnosis and treatment of cancer:I
03/19/2009US20090074664 Cyclic azapeptides as integrin markers
03/19/2009US20090074663 Peptide for diagnosing, preventing and treating atherosclerosis and uses thereof
03/19/2009CA2737126A1 Novel p2x7 epitopes
03/19/2009CA2731204A1 Use of a peptide as a therapeutic agent
03/19/2009CA2704726A1 Use of a defensin peptide as a therapeutic agent
03/19/2009CA2699550A1 Method of inhibiting clostridium difficile by administration of oritavancin
03/19/2009CA2699521A1 Methods and related compositions using specific flavonoids and indanes to reduce weight and inhibit lipase, .alpha.-amylase and .alpha.-glucosidase activity in mammals
03/19/2009CA2699467A1 Peptide sequences and compositions
03/19/2009CA2699429A1 Recombinant preparation of selected bromelain fractions
03/19/2009CA2699376A1 Gene signature for the prediction of radiation therapy response
03/19/2009CA2699222A1 Use of a peptide as a therapeutic agent
03/19/2009CA2699215A1 (d-leu7 ) -histrelin as a therapeutic agent
03/19/2009CA2699167A1 Use of a peptide as a therapeutic agent
03/19/2009CA2699026A1 Use of a peptide as a therapeutic agent
03/19/2009CA2699020A1 Use of a peptide as a therapeutic agent
03/19/2009CA2699012A1 Use of a peptide as a therapeutic agent
03/19/2009CA2699010A1 Use of a peptide as a therapeutic agent
03/19/2009CA2699008A1 Use of a peptide as a therapeutic agent
03/19/2009CA2699006A1 Use of a peptide as a therapeutic agent
03/19/2009CA2698992A1 Use of a peptide as a therapeutic agent
03/19/2009CA2698990A1 Mitogen-activated protein kinase kinase kinase 14 (map3k14) polymorphisms as indicators of subject outcome in critically ill subjects
03/19/2009CA2698985A1 Use of a peptide as a therapeutic agent
03/19/2009CA2698984A1 Use of a peptide as a therapeutic agent
03/19/2009CA2698981A1 Use of a peptide as a therapeutic agent
03/19/2009CA2698980A1 Use of a peptide as a therapeutic agent
03/19/2009CA2698978A1 Use of human neuropeptide af as a therapeutic agent
03/19/2009CA2698977A1 Use of c-type natriuretic peptide, alone or incombination with neuropeptide af, as a therapeutic agent
03/19/2009CA2698976A1 Use of a peptide as a therapeutic agent
03/19/2009CA2698974A1 Use of a peptide as a therapeutic agent
03/19/2009CA2698971A1 Use of urodilatin as a therapeutic agent
03/19/2009CA2698968A1 Use of a peptide as a therapeutic agent
03/19/2009CA2698966A1 Use of fertirelin and delta-endorphin as therapeutic agents
03/19/2009CA2698963A1 Use of a peptide as a therapeutic agent
03/19/2009CA2698912A1 Use of a peptide as a therapeutic agent
03/19/2009CA2698855A1 Use of a peptide as a therapeutic agent
03/19/2009CA2698852A1 Use of a peptide as a therapeutic agent
03/19/2009CA2698833A1 Use of a peptide as a therapeutic agent
03/19/2009CA2698831A1 Use of a peptide as a therapeutic agent
03/19/2009CA2698828A1 Use of a peptide as a therapeutic agent
03/19/2009CA2698824A1 Use of peptide yy, alone or in combination with glucagon-like peptide, for use in medicine
03/19/2009CA2698822A1 Minigastrin as a therapeutic agent
03/19/2009CA2698821A1 Use of a peptide as a therapeutic agent
03/19/2009CA2698789A1 Use of a peptide as a therapeutic agent
03/19/2009CA2698786A1 Use of a peptide as a therapeutic agent
03/19/2009CA2698783A1 Use of a peptide as a therapeutic agent
03/19/2009CA2698778A1 Use of a peptide as a therapeutic agent
03/19/2009CA2698770A1 Use of secretin and optionally urodilatin as a therapeutic agents
03/19/2009CA2698759A1 Use of a peptide as a therapeutic agent
1 ... 815 816 817 818 819 820 821 822 823 824 825 826 827 828 829 830 831 832 833 834 835 ... 3163